EZH2 and myeloid neoplasm: Although a reduction of EZH2 levels and H3K27me3 can be achieved by DNA demethylation agents in combination with histone deacetylation inhibitors [99,103], it remains to be proved if such a therapeutic approach can be effective for EZH2-defective myeloid malignancies.